Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) Shares Outstanding (Diluted Average) (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) changed 0.37% year-over-year to $7.3 million; the TTM value through Dec 2025 reached $7.3 million, changed 0.37%, while the annual FY2025 figure was $7.3 million, 0.37% changed from the prior year.
  • Shares Outstanding (Diluted Average) hit $7.3 million in Q4 2025 for Kezar Life Sciences, roughly flat from $7.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $72.4 million in Q2 2023 and bottomed at $6.7 million in Q4 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $30.3 million, with a median of $7.3 million recorded in 2025.
  • Year-over-year, Shares Outstanding (Diluted Average) soared 39.63% in 2022 and then plummeted 89.95% in 2023.
  • Kezar Life Sciences' Shares Outstanding (Diluted Average) stood at $52.8 million in 2021, then plummeted by 87.23% to $6.7 million in 2022, then increased by 7.7% to $7.3 million in 2023, then rose by 0.48% to $7.3 million in 2024, then increased by 0.37% to $7.3 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $7.3 million, $7.3 million, and $7.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.